Dive Temporary:
- Group Well being Methods on Tuesday offered a few of its ambulatory outpatient laboratory providers to Labcorp for about $194 million in money earlier than transaction bills.
- The deal consists of belongings in 13 states, together with affected person service facilities and in-office phlebotomy places, based on a press launch from CHS.
- CHS will proceed to function its inpatient and emergency division labs and supply lab providers for imaging, pre-admission testing and different hospital-based providers.
Dive Perception:
The businesses say the deal, which was first introduced in July, will profit sufferers by giving them broader entry to Labcorp’s providers, together with its specialty testing menu, suite of information analytics and digital instruments.
It additionally permits CHS to refocus on its core choices, stated CHS President and interim CEO Kevin Hammons in a press launch.
“Finishing this transaction with Labcorp permits our well being techniques to deal with core providers and enhance the general affected person expertise, aligning with our unwavering dedication to offering high-quality, accessible healthcare to our communities,” stated Hammons.
CHS has been realigning its portfolio to deal with revenue-generating providers, together with outpatient care. The for-profit operator has divested quite a few acute care hospitals, together with amenities in North Carolina and Mississippi. The operator is at present engaged on closing offers to promote three hospitals in Pennslyvania and a facility in Tennessee.
In the meantime, Labcorp is increasing.
Labcorp paid about $839 million final yr to accumulate medical and outreach companies together with Baystate Medical Heart, Windfall Medical Basis, Westpac Labs, Invitae and BioReference Well being. In 2023, the corporate spent roughly $671.5 million on acquisitions.
